Cathepsin S inhibitors

Bibliography

• LEUNG-TOUNG R, LI W, TAM TF, KARIMIAN K: Thiol-dependent enzymes and their inhibitors: a review. Curr. Med. Rev (2002) 9:979–1002.
   Google Scholar
• LECAILLE F, KALETA J, BROEMME D: Human and parasitis papain-like cysteine proteases: their roles in physiology and pathology and recent developments in inhibitor design. Chem. Rev (2002) 102:4459–4488.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of cysteineproteases involvement in diseases and their inhibitors.
   Google Scholar
• KIM W, KANG K: Recent developments of cathepsin inhibitors and their selectivity. Expert Opin. Ther. Patents (2002) 12(3):419–432.
   Web of Science ®Google Scholar
• •Detailed review of cathepsin inhibitors.
   Google Scholar
• SCHIRMEISTER T, KAEPPLER U: Non-peptidic inhibitors of cysteine proteases. Mini Review Med. Chem. (2003) 3:361–373.
   PubMed Web of Science ®Google Scholar
• OTTO H-H, SCHIRMEISTER T: Cysteine proteases and their inhibitors. Chem. Rev (1997) 97:133–171.
   PubMed Web of Science ®Google Scholar
• •In depth review of different classes of cysteine protease inhibitors.
   Google Scholar
• SHI GP, MUNGER JS, MEARA JP, RICH DH, CHAPMAN HA: Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. Biol. Chem (1992) 267:7258–7262.
   Web of Science ®Google Scholar
• MACIEWICZ RA, ETHERINGTON DJ: A comparison of four cathepsins (B, L, N and S) with collagenolyfic activity from rabbit spleen. Biochem. .1 (1998) 256:433–440
   Google Scholar
• CHAPMAN HA, RIESE RJ, SHI GP: Emerging roles for cysteine proteases in human biology. Ann. Rev Physiol (1997) 59:63–88.
   PubMed Web of Science ®Google Scholar
• SUKHOVA GK, ZHANG Y, PAN J-H et al.: Deficiency of cathepsin S reduces atheroslerosis in LDL receptor-deficient Clini. Invest. (2003) 111(6):897–906.
   Google Scholar
• ••Evidence supporting the use of cathepsin Sinhibitors for the treatment of atherosclerosis.
   Google Scholar
• SHI G-P, VILLADANGOS JA, DRANOFF G et al.: Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunio, (1999) 10:197–206.
   PubMed Web of Science ®Google Scholar
• RIESE RJ, MITCHELL RN, VILLADANGOS JA et al.: Cathepsin S activity regulates antigen presentation and immunity. Clin. Invest. (1998) 101(11) :2351–2363.
   Google Scholar
• NAKAGAWA TY, BRISSETTE WH, LIRA PD et al.: Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S-null mice. Immunity (1999) 10:207–217.
   PubMed Web of Science ®Google Scholar
• ••Evidence suggesting the use of cathepsin Sinhibitors for the treatment of RA.
   Google Scholar
• SAEGUSA K, ISHIMARU N, YANAGI K et al.: Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. I Clin. Invest (2002) 110(3):361–369.
   PubMed Web of Science ®Google Scholar
• •Evidence supporting the use of cathepsin S inhibitors for the treatment of autoirnmune diseases.
   Google Scholar
• PAULY TA, SULEA T, AMMIRATI M et al.: Specificity determinants of human cathepsin S revealed by crystal structures of complexes. Biochem. (2003) 42(11):3203–3213.
   PubMed Web of Science ®Google Scholar
• ••An in dept evaluation of differences inS3-S3 binding region of related cathepsins.
   Google Scholar
• LOWE G, YUTHAVONG Y: Kinetic specificity in papain-catalyzed hydrolyses. Biochem. J. (1971) 124(1):107–115.
   PubMed Web of Science ®Google Scholar
• WARD YD, THOMSON DS, FRYE LL et al.: Design and synthesis of dipeptide nitriles as reversible and potent cathepsin S inhibitors. Med. Chem (2002) 45 (25):5471–5482.
   Web of Science ®Google Scholar
• DESAI SN, PANZENBECK MJ, WHITE DM et al.: An orally active inhibitor of cathepsin s inhibits human trans vivo DTH. Inflamm. Res. (2003) 52 (Suppl 2): 7.1.
   Google Scholar
• NO AUTHORS LISTED: Carbamate-based reversible inhibitors of cathepsin S and cathepsin K. Expert Opin. Ther. Patents (2003) 13(7):1077–1080.
   Web of Science ®Google Scholar
• GREENSPAN PD, CLARK KL, TOMMASI RA et al.: Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design. Med . Chem. (2001) 44:4524–4534.
   Web of Science ®Google Scholar
• GREENSPAN PD, CLARK KL, COWEN SD et al.: N-Arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin B. Bioorg. Med. Chem. Lett. (2003) 13:4121–4124.
   PubMed Web of Science ®Google Scholar
• FENWICK AE, GRIBBLE AD, IFE RJ, STEVENS N, WITHERINGTON J: Diastereoselective synthesis, activity and chiral stability of cyclic alkoxyketone inhibitors of cathepsin K. Bioorg. Med. Chem. Lett. (2001) 11(2):199–202.
   PubMed Web of Science ®Google Scholar
• FEN WICK AE, GARNIER B, GRIBBLE AD, IFE RJ, RAWLINGS AD, WITHERINGTON J: Solid-phase synthesis of cyclic alkoxyketones, inhibitors of the cysteine protease cathepsin K. Bioorg. Med. Chem. Lett (2001) 11(2):195–198.
   PubMed Web of Science ®Google Scholar
• MAYER RJ, PETRONE AL, KEIJ J, YAMASHITA D, POD OLIN P: The effect of cathepsin S inhibition on antigen presentation in human CD14+- derived cells. Inflammation Research Association - 11th National Conference, Bolton Landing, NY, USA (2002) Abs A61.
   Google Scholar
• MARQUIS RW, RU Y, LOCASTRO SM et al.: Azepanone-based inhibitors of human and rat cathepsin K. Med. Chem. (2001) 44(9):1380–1395.
   Web of Science ®Google Scholar
• ZHOU NE, GUO D, THOMAS G et al: 3-Acylamino-azetidin-2-one as a novel class of cysteine protease inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:139–141.
   PubMed Web of Science ®Google Scholar
• SINGH R, MICETICH R: Mono-P-lactams as enzyme inhibitors. LOrugs (2000) 3(5):512–517.
   Google Scholar
• NORMAN P: Highlights from the third RSC-SCI symposium on proteinase inhibitor design: Proteinase 2002, held May 13-14, 2002, in London, United Kingdom. Drug News Prospect (2002) 15 (6):372–382.
   PubMedGoogle Scholar